REG - Retroscreen Vlgy Grp - Board Change <Origin Href="QuoteRef">RVG.L</Origin>

hVIVOAnnouncement

06/09/2014 16:25

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140714:nRSN1652Ma


RNS Number : 1652M
Retroscreen Virology Group PLC
14 July 2014 
 
For immediate release 07.00: 14 July 2014 
 
RETROSCREEN VIROLOGY GROUP PLC 
 
("Retroscreen" or the "Company") 
 
BOARD CHANGE 
 
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO human
challenge models of disease, is pleased to announce that Dr Alison Fielding
has been appointed as a Non-Executive Director of the Company with immediate
effect. 
 
Alison is a highly respected, entrepreneurial leader, executive coach and
mentor with extensive board experience in both Executive and Non-Executive
capacities in public, private and not-for-profit sectors. She has a track
record of creating and building high-performing companies based on scientific
innovation. 
 
Alison is Director of IP Impact at IP Group plc, a leading UK intellectual
property commercialisation company. She co-founded Techtran Group Limited and
was the Chief Operating Officer of Techtran when it was acquired by IP Group
in January 2005. She was a Director of IP Group from January 2005 to June
2013, promoted to Chief Technology officer in March 2007 and then Chief
Operating Officer in May 2011. She spent six years at McKinsey & Co from 1994
to 2000, where she consulted primarily to the pharmaceutical and health care
sectors. Prior to McKinsey, she spent four years as a development chemist for
Zeneca, performing technical roles in the speciality chemicals and
agrochemicals divisions. Alison holds an MBA from Manchester Business School,
a Ph.D. in Organic Chemistry and a first class degree in Chemistry from the
University of Glasgow. 
 
Kym Denny, Chief Executive Officer, commented, "I am delighted to welcome
Alison to Retroscreen's newly shaped Board, at this exciting juncture in the
Company's development. Alison has a tremendous track record of working with
growth companies in the life science sector to achieve their potential. We
look forward to benefitting from her expertise, as we actively broaden
Retroscreen's capabilities in our quest to leverage fully our unique hVIVO
technology platform." 
 
Dr Alison Margaret Fielding (49) is a director/ partner or has been a
director/ partner of the following companies/ partnerships during the previous
five years: 
 
Current 
 
Getech Group plc 
 
Green Chemicals plc 
 
Perachem Limited 
 
Tissue Regenix Group plc 
 
Previous 
 
Amaethon Limited 
 
Amaethon Trustees Limited 
 
Care International UK 
 
COE Group plc 
 
Crysalin Limited 
 
Fusion IP plc 
 
IP Group Plc 
 
IP2IPO Limited 
 
IP2IPO Services Limited 
 
IP Industry Partners Limited 
 
Techtran Group Limited 
 
Techtran Limited 
 
Techtran Corporate Finance Limited 
 
Techtran Investments Limited 
 
Techtran Services Limited 
 
Pure Polymers Limited 
 
Top Technology Ventures Limited 
 
The Foundation for Social Entrepreneurs 
 
Dr Fielding holds 24,320 ordinary shares in the Company, which were acquired
prior to the Company's IPO in May 2012. 
 
Save for the information disclosed above there is no other information to be
disclosed on Dr Fielding under Schedule 2(g) of the AIM Rules. 
 
For further information please contact: 
 
Retroscreen Virology Group plc                                                
        +44 207 756 1300 
 
Kym Denny (CEO) 
 
Graham Yeatman (FD) 
 
Numis Securities Limited                                                      
            +44 207 260 1000 
 
Michael Meade / Freddie Barnfield (Nominated Adviser) 
 
James Black / Michael Burke (Corporate Broking) 
 
Notes to Editors: 
 
Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing UK life
sciences company pioneering a technology platform called hVIVO which uses
human models of disease involving healthy volunteers to study new drugs and
investigate disease in a safe, controlled environment. 
 
Retroscreen has established itself as the world leader in this field through
the provision of clinical services to third party study sponsors.  To date,
the Company has conducted over 35 clinical studies, involving more than 1600
volunteers for a range of leading industry, governmental and academic
clients. 
 
However, Retroscreen's hVIVO platform has a much wider application in helping
to understand illness better because the Company believes that the best way to
understand human disease is by studying it in humans, not laboratory models. 
 
This information is provided by RNS
The company news service from the London Stock Exchange